Lyell Immunopharma
Focus: Lyell Immunopharma develops curative cell-based immunotherapies targeting oncology and immunology indications. The company operates as a clinical-stage biotech focused on next-generation CAR-T and cellular immunotherapy platforms.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Open Jobs
0
About Lyell Immunopharma
AI assessmentNot HiringNo open roles listed right now. Follow Lyell Immunopharma to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
A Biomarker Screening Protocol for Participants With Solid Tumors
Triple Negative Breast CancerClinical Trials (1)
NCT05891197A Biomarker Screening Protocol for Participants With Solid Tumors
N/AHelp build intelligence for Lyell Immunopharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.